NCLEX RN Practice Question # 421

Free NCLEX Practice Questions.

Take Practice Question # 421.

MONOCLONAL ANTIBODY

Description

• Omalizumab (Xolair) is a recombinant DNAderived humanized immunoglobulin G (IgG) murine monoclonal antibody that selectively binds to IgE to limit the release of mediators in the allergic response.
• Used to treat allergy-related asthma; administered subcutaneously every 2 to 4 weeks
• Dose is titrated based on the serum IgE level and body weight.
• Contraindicated in those with hypersensitivity to the medication

 Side effects

• Injection site reactions
• Viral infections
• Upper respiratory infections
• Sinusitis
• Headache
• Pharyngitis
• Anaphylaxis
• Malignancies

 Interventions

• Assess respiratory rate, rhythm, and depth and auscultate lung fields bilaterally.
• Assess for allergies and/or allergic reaction symptoms such as rash or urticaria.
• Instruct the client that respiratory improvement will not be immediate.
• Instruct the client not to stop taking or decrease the currently prescribed asthma medications unless instructed.
• Avoid live virus vaccines for the duration of treatment.
• Have medications for the treatment of severe hypersensitivity reactions available during ini